Arjuna Natural is investing more than 10% of its total turnover in a clinical research programme to explore the health benefits of its turmeric curcumin, a potent antioxidant, and other new healthy ingredients, all to be launched in 2016.
This includes a total investment of more than USD1.5 million in studies on curcumin alone.
Extensive research is being conducted in leading universities and institutes in India, Australia, Italy, the US and Japan on BCM-95, Arjuna’s leading all-natural curcumin. Twelve clinical studies of turmeric curcumin, covering a range of conditions that include depression, Alzheimer disease, cancer and others, are ongoing. Arjuna holds 12 patents for BCM-95 worldwide, and has several additional patents pending.
“We differentiate our turmeric curcumin through a practice of extensive research and development,” explained Benny Antony, joint managing director for Arjuna. “BCM-95 is the most researched bioavailable curcumin on the market, with a majority share in the US.”
Arjuna’s curcumin is said to be highly bio-available due to the synergy between the curcumin and the compound ar-turmerone, an essential oil component of turmeric. The patented formulation method, produced in Arjuna’s own facility, involves extracting the maximum amount of free curcumin, without synthetic additives. All raw materials used are completely traceable. The company says that this ensures BCM-95 is the most trusted bio-available source of curcumin. It adds that 24 studies support the health benefits of BCM-95 Curcumin extract.
Trust worthy ingredient
“Arjuna meets the new European 2015/1933 PAH regulation that sets maximum levels of PAHs in food supplements,” added Antony. “This bio-active ingredient is clean of pesticides and heavy metals. Arjuna invested in the most advanced quality control equipment to meet the new EU regulations, and to ensure all products are clean and safe. The growing global demand for curcumin, and consumer expectations of pure formulations, encouraged Arjuna to develop a clean, GMO-free ingredient that consumers can trust.”
Arjuna’s R&D centre employs 40 scientists, comprising 10% of its employees, and with women occupying 50% of lead positions. The scientists work full-time in bench research and monitoring clinical studies for various applications in the dietary supplement and pharmaceutical industries.
Arjuna will present the most recent clinical study results on curcumin for mental health disorders at the Vitafoods, Europe conference, May 10-12 2016 in Geneva.
Arjuna states that its production processes and products meet market-specific regulations worldwide. The company has achieved international certifications including ISO22000, Kosher and Halal. It continues to engage in research and development, with continuing scientific validation of its novel product line through advanced clinical studies.